ghk-cu modulates 4000 genes GHK-Cu 100mg Copper Peptide |

& Tlaskalov-Hogenov, H

Weeks 1-4: Foundation phase The first month establishes tolerance and begins the cellular changes that eventually produce visible results

Currently, treatments based on copper metabolism in cardiovascular disease can encompass a wide range of options, including copper chelating agents [such as triethylenetetramine (TETA), tetrathiomolybdate (TTM) and disodium ethylene diamine tetraacetic acid (EDTA)], small-molecule inhibitors of copper chaperone proteins (such as DCAL50), copper ion carriers and natural antidote agents (Table II)

It tracks closely with the metabolic deterioration that characterizes the third and fourth decades of life: rising fasting insulin, expanding visceral adipose tissue, declining mitochondrial density in skeletal muscle, and blunted exercise adaptability